MiR-363 sensitizes cisplatin-induced apoptosis targeting in Mcl-1 in breast cancer

Medical Oncology

Volumn 31, Issue 12, 2014, Pages 1-10

  Zhang, Ruiguang ^a   Li, Yan ^a   Dong, Xiaochuan ^a   Peng, Li ^a   Nie, Xiu ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Apoptosis; Breast cancer; Cisplatin; Mcl 1; MDA MB 231; microRNA 363 (miR 363)

Indexed keywords

CISPLATIN; MICRORNA; MICRORNA 363; PROTEIN MCL 1; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; ANTINEOPLASTIC AGENT; MCL1 PROTEIN, HUMAN; MIRN363 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER RESISTANCE; CELL VIABILITY; CYTOTOXICITY; DOWN REGULATION; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; WESTERN BLOTTING; BREAST TUMOR; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICRORNAS; MOLECULAR TARGETED THERAPY; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; TRANSFECTION;

EID: 84919909788     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0347-3     Document Type: Article

References (45)

1. Prabhakaran P, Hassiotou F, Blancafort P, Filgueira L. Cisplatin induces differentiation of breast cancer cells. Front Oncol. 2013;3:134.
2. Colombo PE, Milanezi F, Weigelt B, Reis-Filho JS. Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction. Breast Cancer Res. 2011;13(3):212.
3. Guarneri V, Conte P. Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy. Oncologist. 2009;14(7):645–56.
4. Cobleigh MA. Other options in the treatment of advanced breast cancer. Semin Oncol. 2011;38(Suppl 2):S11–6.
5. Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, et al. Systems biology ofcisplatin resistance: past, present and future. Cell Death Dis. 2014;5:e1257.
6. Cohen SM, Lippard SJ. Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol. 2001;67:93–130.
7. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev. 2007;87(1):99–163.
8. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869–83.
9. Castedo M, Coquelle A, Vivet S, Vitale I, Kauffmann A, Dessen P, et al. Apoptosis regulation in tetraploid cancer cells. EMBO J. 2006;25(11):2584–95.
10. Michaud WA, Nichols AC, Mroz EA, Faquin WC, Clark JR, Begum S, et al. Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. Clin Cancer Res. 2009;15(5):1645–54.
11. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.
12. Winter J, Jung S, Diederichs S, et al. Many roads tomaturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol. 2009;11(3):228–34.
13. Song YX, Yue ZY, Luo Y, et al. MicroRNA-148b is frequently down-regulated in gastric cancer and acts as a tumor suppressor by inhibiting cell proliferation. Mol Cancer. 2011;10:1.
14. Cheng AM, Byrom MW, Shelton J, Ford LP. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 2005;33(4):1290–7.
15. Qiao J, Lee S, Paul P, Theiss L, Tiao J, Qiao L, Kong A, Chung DH. miR-335 and miR-363 regulation of neuroblastoma tumorigenesis and metastasis. Surgery. 2013;154(2):226–33.
16. Sun Q, Zhang J, Cao W, Wang X, Xu Q, Yan M, Wu X, Chen W. Dysregulated miR-363 affects head and neck cancer invasion and metastasis by targeting podoplanin. Int J Biochem Cell Biol. 2013;45(3):513–20.
17. Thomas L, Lam C, Edwards S. Mcl-1 the molecular regulation of protein function. FEBS Lett. 2010;584(14):2981.
18. Chen C, Ridzon DA, Lee DH, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005;33(20):e179.
19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–8.
20. Tong SJ, Liu J, Wang X, Qu LX. microRNA-181 promotes prostate cancer cell proliferation by regulating DAX-1 expression. Exp Ther Med. 2014;8(4):1296–300.
21. Zhang Z, Zheng L, Zhao Z, Shi J, Wang X, Huang J. Grape seed proanthocyanidins inhibit H2O2-induced osteoblastic MC3T3-E1 cell apoptosis via ameliorating H2O2-induced mitochondrial dysfunction. J Toxicol Sci. 2014;39(5):803–13.
22. Varadarajan S, Butterworth M, Wei J, Pellecchia M, Dinsdale D, Cohen GM. Sabutoclax (BI97C1) and BI112D1, putative inhibitors of MCL-1, induce mitochondrial fragmentation either upstream of or independent of apoptosis. Neoplasia. 2013;15(5):568–78.
23. Prathapan A, Vineetha VP, Raghu KG. Protective effect of Boerhaavia diffusa L. against mitochondrial dysfunction in angiotensin II induced hypertrophy in H9c2 cardiomyoblast cells. PLoS ONE. 2014;9(4):e96220.
24. Kelly PN, Strasser A. The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ. 2011;18(9):1414–24.
25. Vinothini G, Murugan RS, Nagini S. Mitochondria-mediated apoptosis in patients with adenocarcinoma of the breast: correlation with histological grade and menopausal status. Breast. 2011;20(1):86–92.
26. Luo L, Zhang T, Liu H, Lv T, Yuan D, Yao Y, et al. MiR-101 and Mcl-1 in nonsmall-cell lung cancer: expression profile and clinical significance. Med Oncol. 2012;29(3):1681–6.
27. Zhang T, Zhao C, Luo L, Zhao H, Cheng J, Xu F. The expression ofMcl-1 in human cervical cancer and its clinical significance. Med Oncol. 2012;29(3):1985–91.
28. Zhang Z, Teruya K, Yoshida T, Eto H, Shirahata S. Fucoidan extract enhances the anti-cancer activity of chemotherapeutic agents in MDA-MB-231 and MCF-7 breast cancer cells. Mar Drugs. 2013;11(1):81–98.
29. Ren LH, Chen WX, Shi RH, et al. MicroRNA-183 promotes proliferation and invasion in oesophageal squamous cell carcinoma by targeting programmed cell death 4. Br J Cancer. 2014; [Epub ahead of print].
30. Qin Y, Dang X, Li W, Ma Q. miR-133a functions as a tumor suppressor and directly targets FSCN1 in pancreatic cancer. Oncol Res. 2013;21(6):353–63.
31. Lei SL, Zhao H, Yang Q, et al. Regulatory roles of microRNA-708 and microRNA-31 in proliferation, apoptosis and invasion of colorectal cancer cells. Oncol Lett. 2014;8(4):1768–74.
32. Ng SB, Yan J, Huang G, Selvarajan V, Tay JL, Lin B, et al. Dysregulated microRNAs affect pathways and targets of biologic relevance in nasal-type natural killer/T-cell lymphoma. Blood. 2011;118(18):4919–29.
33. Sun Q, Zhang J, Cao W, Wang X, Xu Q, Yan M, Wu X, Chen W. Dysregulated miR-363 affects head and neck cancer invasion and metastasis by targeting podoplanin. Int J Biochem Cell Biol. 2013;45(3):513–20.
34. Ru P, Steele R, Hsueh EC, Ray RB. Anti-miR-203 upregulates SOCS3 expression in breast cancer cells and enhances cisplatin chemosensitivity. Genes Cancer. 2011;2(7):720–7.
35. Sun L, Yao Y, Liu B, Lin Z, Lin L, Yang M, Zhang W, Chen W, Pan C, Liu Q, Song E, Li J. MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene. 2012;31(4):432–45.
36. Decatris MP, Sundar S, O’Byrne KJ. Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer Treat Rev. 2004;30(1):53–81.
37. Tsimberidou AM, Braiteh F, Stewart DJ, Kurzrock R. Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized trial. J Clin Oncol. 2009;27(36):6243–50.
38. Dhar S, Kolishetti N, Lippard SJ, Farokhzad OC. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci USA. 2011;108(5):1850–5.
39. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2(1):48–58.
40. Fang Y, Wang L, Xia GH, Shi MQ. Clinical investigation of efficacy of albumin bound paclitaxel plus platinum compounds as first-line chemotherapy for stage III/IV squamous non-small cell lung cancer. Asian Pac J Cancer Prev. 2014;15(17):7453–7.
41. Xu XM, Zhang Y, Qu D, Liu HB, Gu X, Jiao GY, Zhao L. Combined anticancer activity of osthole and cisplatin in NCI-H460 lung cancer cells in vitro. Exp Ther Med. 2013;5(3):707–10.
42. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81.
43. Zhao JX, Liu H, Lv J, Yang XJ. Wortmannin enhances cisplatin-induced apoptosis in human ovarian cancer cells in vitro. Eur Rev Med Pharmacol Sci. 2014;18(17):2428–34.
44. Zu Y, Yang Z, Tang S, Han Y, Ma J. Effects of p-glycoprotein and its inhibitors on apoptosis in k562 cells. Molecules. 2014;19(9):13061–75.
45. Takahashi H, Chen MC, Pham H, Matsuo Y, Ishiguro H, Reber HA, Takeyama H, Hines OJ, Eibl G. Simultaneous knock-down of Bcl-xL and Mcl-1 induces apoptosis through Bax activation in pancreatic cancer cells. Biochim Biophys Acta. 2013;1833(12):2980–7.